Actively Recruiting
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
Led by Salubris Biotherapeutics Inc · Updated on 2026-01-20
30
Participants Needed
1
Research Sites
93 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH. At least 20 and up to approximately 30 participants will be enrolled and receive JK07 high dose in this open-label trial.
CONDITIONS
Official Title
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with heart failure classified as New York Heart Association Class II-III
- Participants classified as having HFrEF (LVEF 64 40%) or HFpEF (LVEF >40% and 6470%)
- Evidence of combined post- and pre-capillary pulmonary hypertension (cpcPH) confirmed by right heart catheterization with:
- Pulmonary vascular resistance (PVR) 652.5 Wood units
- Mean pulmonary arterial pressure (mPAP) 6525 mmHg
- Pulmonary artery wedge pressure (PAWP) 6516 mmHg
You will not qualify if you...
- Diagnosis of pulmonary hypertension in WHO Group 1, Group 3, Group 4, or Group 5
- Contraindication to right heart catheterization that can remain in place for approximately 6 hours
- Pre-existing lung diseases including congenital abnormalities, full or partial pneumonectomy, or prior therapeutic radiation of lungs or mediastinum
- Body mass index (BMI) greater than 45 kg/m at screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Saint Francis Heart and Vascular Institute
Tulsa, Oklahoma, United States, 74136
Actively Recruiting
Research Team
A
Amanda McEwen
CONTACT
A
Ashleigh Chasteen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here